Mizoguchi Y, Shin T, Sakagami Y, Seki S, Kuroki T, Kobayashi K, Yamamoto S, Morisawa S
Third Department of Internal Medicine, Osaka City University Medical School, Japan.
Gastroenterol Jpn. 1988 Apr;23(2):147-52. doi: 10.1007/BF02799026.
Changes in peripheral blood immunological effector cells after systemic administration of recombinant interleukin 2 (rIL2) were studied in 14 patients with HBe antigen-positive chronic hepatitis. The patients were intravenously injected with rIL2 for 4 weeks, and the experiments were performed using mononuclear cells isolated from the peripheral blood during and after rIL2 administration. No significant changes in OKT4-positive cell population, OKT8-positive cell population, OKT4/OKT8 ratio and Leu7-positive cell population were detected during and after intravenous injection of rIL2. However, the natural killer (NK) cell and lymphokine-activated killer (LAK) cell activities significantly increased in the fourth week of rIL2 administration, while the K cell activity in the antibody-dependent cell-mediated cytotoxicity reaction, antibody response, lectin-induced lymphocyte transformation and IL1 production of LPS-stimulated monocytes were not affected. These results suggest that IL2 increases the NK cell and LAK cell activities in vivo.
对14例HBe抗原阳性慢性肝炎患者进行了研究，观察重组白细胞介素2（rIL2）全身给药后外周血免疫效应细胞的变化。患者静脉注射rIL2共4周，并在rIL2给药期间及给药后使用从外周血分离的单核细胞进行实验。静脉注射rIL2期间及之后，未检测到OKT4阳性细胞群、OKT8阳性细胞群、OKT4/OKT8比值和Leu7阳性细胞群有显著变化。然而，在rIL2给药的第四周，自然杀伤（NK）细胞和淋巴因子激活的杀伤（LAK）细胞活性显著增加，而抗体依赖性细胞介导的细胞毒性反应中的K细胞活性、抗体反应、凝集素诱导的淋巴细胞转化以及脂多糖刺激的单核细胞的IL1产生均未受影响。这些结果表明，IL2在体内可增加NK细胞和LAK细胞活性。
